Compare Becton Dickinson and Co (BDX) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Raytheon Technologies Corp — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Raytheon Technologies Corp trades at $193.9 (market cap $260.44B). The key difference: Raytheon Technologies Corp is far larger — about 6.3× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | RTX | |
|---|---|---|
Market Cap | $41.51B | $260.44B |
Sector | Health | Industrials |
52-Week High | $185.39 | $212.16 |
52-Week Low | $135.49 | $148.68 |
Enterprise Value | $57.97B | $292.55B |
Dividend Yield | 2.79% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
RTX trades at $196.39, up 0.23% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $1.78 surpassing the $1.51 expectation. Revenue grew to $88.6B in 2025, and net income margin improved to 8.03%. The company secured a $515 million Navy contract for SPY-6 radars, highlighting defense sector strength. Cash flow from operations reached $10.57B in 2025, supporting dividend payments and strategic investments.
The outlook for RTX is positive, driven by robust defense contracts, earnings growth, and a consensus price target of $213. Risks include reliance on government spending, competitive pressures, and macroeconomic volatility. Institutional sentiment remains bullish with 69% buy ratings, but investors should monitor debt levels and execution on production targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
